A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
Latest Information Update: 18 Apr 2025
At a glance
- Drugs Cemiplimab (Primary) ; Ubamatamab (Primary) ; Ubamatamab (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 04 Jun 2024 According to a trial design for phase 2 cohort, presented at the 60th Annual Meeting of the American Society of Clinical Oncology, the study is currently enrolling to these OC and EC expansion cohorts.
- 04 Jun 2024 Trial design for phase 2 cohort, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 29 Mar 2024 Results (n=12) assessing Pharmacokinetics (Pk), Serum Cytokines, and Safety Following Intravenous or Subcutaneous Step Up Dosing of Ubamatamab,in Patients with Recurrent Ovarian Cancer presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics